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Abstract
Background: Protease inhibitors (PI’s) and reverse transcriptase drugs are important components of highly active
antiretroviral therapy (HAART) for treating human acquired immunodeficiency syndrome (AIDS). Long-term clinical
therapeutic efficacy and treatment compliance of these agents have been limited by undesirable side-effects, such
as diarrhea. This study aims to investigate the effects of selected antiretroviral agents on intestinal histopathology
and function in vivo and on cell proliferation and death in vitro.
Methods: Selected antiretroviral drugs were given orally over 7 days, to Swiss mice, as follows: 100 mg/kg of
nelfinavir (NFV), indinavir (IDV), didanosine (DDI) or 50 mg/kg of zidovudine (AZT). Intestinal permeability measured
by lactulose and mannitol assays; net water and electrolyte transport, in perfused intestinal segments; and small
intestinal morphology and cell apoptosis were assessed in treated and control mice. In vitro cell proliferation was
evaluated using the WST-1 reagent and apoptosis and necrosis by flow cytometry analysis.
Results: NFV, IDV, AZT and DDI caused significant reductions in duodenal and in jejunal villus length (p < 0.05).
IDV and AZT increased crypt depth in the duodenum and AZT increased crypt depth in the jejunum. NFV, AZT and
DDI significantly decreased ileal crypt depth. All selected antiretroviral drugs significantly increased net water
secretion and electrolyte secretion, except for DDI, which did not alter water or chloride secretion. Additionally,
only NFV significantly increased mannitol and lactulose absorption. NFV and IDV caused a significant reduction in
cell proliferation in vitro at both 24 h and 48 h. DDI and AZT did not alter cell proliferation. There was a significant
increase in apoptosis rates in IEC-6 cells after 24 h with 70 ug/mL of NFV (control: 4.7% vs NFV: 22%) while IDV,
AZT and DDI did not show any significant changes in apoptosis compared to the control group. In jejunal sections,
IDV and NFV significantly increased the number of TUNEL positive cells.
Conclusion: The PI’s, NFV and IDV, increased cell apoptosis in vivo, water and electrolyte secretion and intestinal
permeability and decreased villus length and cell proliferation. NFV was the only drug tested that increased cell
apoptosis in vitro. The nucleoside reverse transcriptase inhibitors, AZT and DDI, did not affect cell apoptosis or
proliferation. These findings may partly explain the intestinal side-effects associated with PI’s.
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Protease inhibitors (PI’s) and reverse transcriptase drugs
(RTs) are important components of highly active antire-
troviral therapy (HAART) for treating human acquired
immunodeficiency syndrome (AIDS) and have signifi-
cantly changed the natural history of AIDS, increasing
life expectancy and quality of life [1,2]. These drugs are
known to reduce human immunodeficiency virus (HIV)
load and increase circulating CD4 T cells, thus resulting
in fewer gastrointestinal conditions, ultimately reducing
hospitalization, and enhancing life expectancy in HIV-
infected individuals [3,4]. However, long-term clinical
therapeutic efficacy and treatment compliance of these
agents have been limited by undesirable side-effects,
such as diarrhea, most commonly seen with ritonavir-
boosted PI’s, and enteric infections, which have been
reported to occur in up to 62% of patients [4-6].
Although life-saving benefits of HAART are well-
known, antiretroviral intestinal side-effects have not
been explored in animal models and the mechanisms of
HAART-induced intestinal epithelial damage in vitro are
still poorly understood. There is a scarcity of in vivo and
in vitro studies that evaluate the effects of these agents
on intestinal barrier function. Bode et al, 2005, reported
decreased transepithelial resistance in HT-29 mono-
layers after treatment with PI’s, accompanied by massive
cell apoptosis but not necrosis [7]. Since these initial
findings, several studies have been conducted both in
vitro and in vivo, suggesting the potential benefits of
HIV PI’s in chemotherapy [8]. Nelfinavir has been
demonstrated to induce endoplasmic reticulum (ER)
stress, autophagy and apoptosis both in vivo and in vitro
and the authors have, therefore, suggested it could be
repositioned as a chemotherapy agent [9]. Another
study demonstrated that PI’s induce secretory diarrhea,
by potentiating muscarinic chloride secretion in T84
cells through amplification and prolongation of an apical
membrane Ca
2+-dependent chloride conductance [10].
Our group has demonstrated that intestinal epithelial
barrier breakdown due to enteric infections and diarrhea
might lead to antiretroviral drug malabsorption and
increased drug resistance [11]. Improvements of gastro-
intestinal symptoms and antiretroviral drug levels were
found with oral glutamine derivatives in a randomized
clinical trial enrolling hospitalized AIDS patients after
seven days of intervention [12]. However, it is of great
importance to further understand the mechanisms
involved in this process in order to optimize possible
future interventions that can lead to a decrease in side
effects such as diarrhea.
The intestinal epithelial barrier is composed of an
extremely dynamic cell population, which behaves dif-
ferently during intestinal adaptation following mucosal
injury [13]. This epithelial lining is renewed with a
highly active cell turn over by means of their surround-
ing crypts, from where stem cells migrate and differenti-
ate towards the villus tip [14-17]. This current study
assessed changes in the intestinal barrier function from
selected anti-retroviral drugs in mice and in intestinal
epithelial cells, thus shedding light on specific drug-host
interactions and intestinal side effects of targeted antire-
troviral therapy.
Methods
Reagents and drugs
Mellibiose and chemicals for enteric perfusion, including
NaCl, KCl, CaCl2,N a H C O 3,a n dN a H 2PO4, and sodium
citrate were obtained from Sigma-Aldrich, St. Louis,
MO. Lactulose and mannitol were purchased from Luit-
pold Produtos Farmacêuticos Ltda., Barueri, SP, and
from Henrifarma Produtos Químicos e Farmacêuticos,
São Paulo, SP, Brazil, respectively. Nelfinavir (NFV),
indinavir (IDV), zidovudine (AZT), and didanosine
(DDI) were kindly granted by the Infectious Diseases’
State Hospital São José, Fortaleza, CE, Brazil, solely for
the purpose of rodent experiments. Tetrazolium salt
WST-1 reagent was obtained from Roche (Mannheim,
Germany). Mitomycin C was obtained from Roche
(Mannheim, Germany). Annexin V Apoalert kit with
Binding buffer was obtained from BD Biosciences (Clo-
netech, Palo Alto, CA). ApopTag Plus Peroxidase In
Situ Detection Kit (Serologicals Corp., Norcross, GA).
AZT, DDI, IDV and NFV used for cell culture com-
pounds were obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH.
Animals
Male Swiss mice weighing 30 to 40 g were obtained
from the Clinical Research Unit & Institute of Biomedi-
cine animal facility (Federal University of Ceara), and
were housed in temperature-controlled rooms prior to
animal experiments. All animals received standard mice
chow diet and water ad libitum. Surgical procedures,
animal handling and treatment were reviewed and
approved by the Animal Care and Use Committee at
the Federal University of Ceara, according to the Brazi-
lian College for Animal Experimentation guidelines
(COBEA).
Treatment regimen
Animals were weighed and randomized into different
t r e a t m e n tg r o u p s .N F V ,I D V ,A Z T ,a n dD D Iw e r e
diluted in sterile phosphate buffer (PBS), as vehicle, and
a control group treated only with PBS. Each group con-
sisted of six or more animals. NFV (100 mg/kg), IDV
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PBS, were given orally by gavage on days 1 through 7.
In order to find an evaluable regimen for testing, we
conducted a pilot study to evaluate survival rates using
the following concentrations: NFV (100 and 300 mg/kg);
IDV (300 mg/kg); AZT (100 and 300 mg/kg) and DDI
(150 and 100 mg/kg). Doses and the experimental
course (one week-treatment) were defined based on the
survival data. All animals were weighed and clinically
examined daily for diarrhea until the study end point.
Data on nutritional intake was not collected during the
time of the experiment. Therefore, we cannot exclude
differences in nutritional intake between the groups.
Histology and Intestinal Morphometry
Mice were sacrificed by a lethal injection of a euthanasia
solution containing chloral hydrate (250 mg/kg, i.p),
under anesthesia, on day 8. Immediately after euthana-
sia, 0.5 cm-samples were harvested from different intest-
inal segments, as follows: duodenum, jejunum, and
ileum, based on anatomical hallmarks. Tissue specimens
were fixed in 10% neutral buffered formalin, and dehy-
drated for 12 h. On the following day, specimens were
cut with a razor blade and then stored in 70% ethanol
for paraffin embedding. 5 um-thick cross-sections were
prepared for hematoxylin-eosin staining (HE). Crypt
depth and villus height were measured from HE stained
slides on a light microscope equipped with a digital
camera, and a computer-aided image capture system.
Villus height was measured from the tip to the villus-
crypt junction. The crypt depth was measured from the
villus-crypt junction to the crypt bottom. At least 10
clear longitudinal sections of the villi and the crypts
were selected randomly from each sample, measured
with an eyepiece ruler and averaged after proper calibra-
tion. All morphometric analyses were conducted blindly
regarding experimental groups and diarrheal outcomes.
Morphologic analyses were carried out by only one
investigator in a blinded manner; hence inter or intra-
individual variability was not assessed.
In vivo Analysis for Cell Death
Analysis of apoptosis or necrosis was performed using
ApopTag Plus Peroxidase In Situ Detection Kit (Serolo-
gicals Corp., Norcross, GA) for TUNEL (terminal deoxy-
nucleotidyltransferase-mediated dUTP-biotin nick end
labeling). The ApopTag Plus Peroxidase. In Situ Detec-
tion Kit distinguishes apoptosis from necrosis by specifi-
cally detecting DNA cleavage and chromatin
condensation associated with apoptosis. However, there
may be some instances where cells exhibiting necrotic
morphology my stain lightly or in rare instance, DNA
fragmentation can be absent or incomplete in induced
apoptosis. Thus, the results were presented as TUNEL
positive cells as recommended [18]. Pariffin-embedded
intestinal tissue samples sections were hydrated and
incubated with 20 μg/ml of proteinase K (Sigma, New
York) for 15 minutes at room temperature (RT). Endo-
genous peroxidase was blocked by treatment with 3%
(wt/vol) hydrogen peroxide in PBS for 5 minutes at RT.
Slides were then washed with PBS and sections were
incubated in a humidified chamber at 37°C for 1 h with
TdT buffer containing TdT enzyme and reaction buffer.
Afterwards, samples were incubated for 10 min at RT
with a stop/wash buffer and then incubated in a humidi-
fied chamber for 30 min with anti-digoxigenin-peroxi-
dase conjugate at RT. Samples were then washed several
times in PBS, the slides were covered with peroxidase
substrate to develop color and then wash in three
changes of distilled H2O and counterstained in 0.5%
(vol/vol) methyl green for 10 minutes at RT. Cell apop-
tosis was measured by counting under a light micro-
scope the number TUNEL positive cells, which
represent apoptotic cells and possibly some necrotic
cells. At least 10 randomly selected sections from each
sample were counted and averaged.
Intestinal Absorption and Permeability
The lactulose/mannitol ratio (L:M) was used in this study
as the primary parameter to evaluate the integrity of the
intestinal barrier function. Mannitol, a monosaccharide,
is considered a biological marker of total intestinal
absorptive area, since it is absorbed transcellularly. In
contrast, lactulose, a disaccharide, is a marker of mucosal
damage, since it is only absorbed paracellularly. Animals
were fed with a low carbohydrate-chow diet on days 5, 6
and 7 of the treatment regimen. On day 7, mice were
fasted overnight (8-12 h) and placed in metabolic cages
(3 animals/cage). On day 8, 0.25 ml of a solution contain-
ing lactulose (20 mg/mL) and mannitol (50 mg/mL) was
given to the experimental mice by gavage. After 1 h the
animals regained access to food and water ad libitum.
The urine was collected during the next 24 hours in a
flask and mixed with a 25 uL-solution containing chlor-
hexidine (40 mg/mL). Total urine volumes were col-
lected, aliquoted to 50 μl and stored at -20°C for further
analyses. Each urine sample (50 ul) was mixed with
50 uL of a solution containing mellibiose (3.6 mM) and
diluted in 2.9 ml of doubled-distilled and deionized
water. After centrifugation and filtration via a Millipore
membrane (0.22 um), a 50 uL-filtered urine solution was
employed for sugar determination using high-perfor-
mance liquid chromatography (HPLC) with pulsed
amperometric detection, as previously described [19].
Urinary recovery of both lactulose and mannitol was cal-
culated as a percentage of the dose ingested.
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On day 7, experimental mice treated either with NFV,
IDV, AZT, DDI or PBS, were fasted for 12 h, with free
access to water ad libitum. Animals were submitted to
intestinal perfusion to evaluate net fluid and electrolyte
transport. After ketamine (35 mg/kg, i.m.) and xylazine
(5 mg/kg, i.m.) anesthesia, a median 3- to 5-cm laparot-
omy was performed for visualization of the small intes-
tine. An approximately 15-cm ileal segment was selected
and washed with 1 ml of phosphate-buffered saline (pH
7.4), and the proximal and distal ends were ligated by
means of polyvinyl cannulas for tissue perfusion. Polyvi-
nyl cannulas (internal diameter 0.08 cm.; outer diameter
0.26 cm; Cole-Parmer Instrument Company, Vernon
Hills, IL) were inserted approximately 5 cm distal to the
ligament of Treitz and 5 cm proximal to the ileocecal
valve (internal diameter, 0.085 in.; outer diameter 0.128
in.; Becton Dickinson, Sparks, MD). Ringer’ss o l u t i o n s
were pre-warmed to 37°C, maintained at pH 7.4, and
introduced through the proximal cannula with the aid
of a motorized pump (Masterflex C/L Pump System,
Model 77120-62; Cole-Parmer Instrument Co.). Perfu-
sion was maintained at the slow rate of 0.16 ml/min
throughout the experiment. Samples were taken every
15 min throughout the 75-min study period for electro-
lyte and osmolarity measurements, as well as for deter-
mination of phenolsulfonphthalein (PSP) concentration.
At the end of the perfusion, the animals were sacrificed,
and the dry weight (after desiccation at 90°C for 72 h)
of the intestinal segment was used to calculate the per-
fusate flow and net water and electrolyte transport.
Biochemical Analyses
PSP (50 ug/ml) was used as a non-absorbable marker
for sodium, potassium, chloride and water net flux cal-
culation. PSP was measured spectrophotometrically
(Spectrophotometer ModelC 3 8 2 ;M i c r o s o n a lS . A ,S ã o
Paulo, SP, Brazil) according to the method developed by
Schedl and Clifton [20]. Sodium and potassium concen-
trations in the perfusate were measured by flame photo-
metry (Flame Photometer Model 443; Instrumentation
Laboratory, Lexington, MA). The colorimetric method
for chloride detection (Labtest Bio. Diagnostics, Belo
Horizonte, MG, Brazil) was used according to the man-
ufacturer’s instructions. The osmolarity of the perfusion
samples was measured with a vapor pressure osmometer
(Model 5100C; Wescor, Logan, UT).
Cell culture
Rat intestinal jejunal crypt cells (IEC-6, passages 8-14)
were purchased from American Type Culture Collection
(Rockville, MD) and were cultured at 37°C in a 5% CO2
incubator. The maintenance cell media was Dulbecco’s
Modified Eagle Media (DMEM; Gibco BRL, Grand
Island, NY) supplemented with 5% Fetal Bovine Serum
(FBS), 5 mg bovine insulin, 50 ug/ml of penicillin/strep-
tomycin (DMEM; Gibco BRL, Grand Island, NY) and a
final concentration of 1 mM of sodium pyruvate. The
media was changed thrice a week, according to standard
culture protocols. The cultured cells were trypsinized
with 0.05% EDTA trypsin when 90-95% confluence was
achieved.
Cell proliferation
Cell proliferation was measured indirectly using the tetra-
zolium salt WST-1 (4-[3-(4-iodophenyl)-2H-5-tetrazolio]-
1-3-benzene disulfonate), according to the manufacturer
recommendations. A 96-well plate was seeded with IEC-6
cells in a total concentration of 4 × 10
3 cells/well in
100 uL of DMEM media. Cells were allowed to attach for
48 hours, when the wells were washed with 100 uL of
DMEM media. The cells were then incubated for 24 and
48 h with either DMEM media or DMEM media incu-
bated with NFV (7 ug/mL, 10 ug/mL, 70 ug/mL and
100 ug/mL), DDI (5 ug/mL, 10 ug/mL, 50 ug/mL and
100 ug/mL), IDV (5 ug/mL, 10 ug/mL, 50 ug/mL
and 100 ug/mL) and AZT (5 ug/mL, 10 ug/mL, 50 ug/ml
and 100 ug/mL). After 24 and 48 hours, wells were incu-
bated for 4 hours with 10 uL of the tetrazolium salt and
the absorbance was measured using an ELISA microplate
reader at 450 nm (reference range 420-480 nm). Tetrazo-
lium salts are cleaved to formazan by mitochondrial
enzymes in viable cells. Enhancement of the number of
viable cells will result in an increase of the amount of the
formazan dye, which is detectable by the ELISA reader.
Therefore, this model indirectly measures cell proliferation
in a time-dependent-manner. The experiments were car-
ried out separately with individual control groups for each
experiment, using different cell passages. Therefore, the
analyses were done comparing values within each indivi-
dual experiment.
Flow Cytometry for Apoptosis and Necrosis
Apoptosis and necrosis were measured by flow cytome-
try analyses using the ApoAlert annexin V kit. Annexin
V is a molecule that binds to phosphatidylserine (PS)
and when conjugated to a fluorochrome detects apopto-
tic cells expressing PS on the reversed membrane sur-
face. For this protocol, propidium iodide was also used
to detect necrotic and late apoptotic cells, which express
propidium iodide inside the membrane. The cells were
seeded on 12-well plates in a concentration of 5 ×
10
5cells/well. These cells were allowed to attach on the
plate surface for 24 hours. Afterwards, cells were washed
with DMEM media and incubated with NFV (70 u/mL),
IDV (100 ug/mL), DDI (100 ug/mL), AZT (100 ug/mL).
After 24 h of incubation, cells were trypsinized, centri-
fuged, and washed with serum-containing media, before
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diluted to 10
5-10
6 cells and rinsed with 1× Binding Buf-
fer, and re-suspended in 200 uL of Binding Buffer. 5 uL
of annexin V and 10 uL of propidium iodide were
added and incubated for 5-15 min in the dark. The sam-
ples were then processed at the University of Virginia’s
Flow Cytometry Core, using a FACS Calibur dual laser
(Becton Dickinson).
Statistical Analyses
Results are expressed as mean ± standard error (SEM), as
generated by GraphPad Prism version 4.0 (GraphPad soft-
ware, San Diego, CA). The differences between the experi-
mental groups were compared by one-way ANOVA,
corrected by Bonferroni’s multiple comparison tests.
Results
1) In vivo experiments
Survival rate and body weight
In order to define possible antiretroviral toxicity in our
murine model, we have tested preliminarily different
concentrations of antiretroviral drugs for 5 consecutive
days. The tested concentrations are as follows: NFV
(100 and 300 mg/kg); IDV (300 mg/kg); AZT (100 and
300 mg/kg) and DDI (150 and 100 mg/kg). The only
group that presented significant toxicity was AZT, fea-
tured by mucous diarrhea, wasting, and death at the
dose of 100 mg/kg (2/8 = 25%) and 300 mg/kg (4/8 =
50%). Therefore, we decided to decrease AZT concen-
tration to 50 mg/kg. The minimum effective and safe
dose of the antiretroviral agents was chosen for the
remainder of the study. In order to assure a longer per-
iod of treatment, we increased the duration of antiretro-
viral therapy to seven days. All animals (at least n = 6
per group) survived throughout the experimental course.
NFV and IDV groups showed significant weight reduc-
tions as early as five treatment days. Seven days follow-
ing treatment all antiretroviral groups showed
significant weight decrements as compared to the
untreated PBS control (p < 0.001), as seen in Figure 1.
Effect of Antiretrovirals on Intestinal Villi Length, Crypt
Depth and Cell Apoptosis
As shown in Figure 2A, antiretroviral drugs strikingly
blunted duodenal villus height at day 8, as compared to
the unchallenged group treated with PBS (p < 0.001).
Proximal and mid-segments of the small intestine were
most affected. IDV was the only drug tested that caused
a significant decrease in ileal villus height. IDV signifi-
cantly reduced villus height throughout the small intest-
inal segments, having a significant blunting effect in
both the duodenum and ileum (p < 0.05). As seen in
Figure 2B, this morphological villus atrophy due to IDV
was accompanied by increased crypt depth in the duo-
denum, and decreased crypt depth in the ileum. Most of
the antiretroviral drugs tested (NFV, IDV and DDI)
decreased the crypt depth in the ileal mucosa. A similar
trend was seen with AZT, albeit not reaching statistical
significance. Interestingly, only AZT induced crypt
hyperplasia in both the duodenum and jejunum, in con-
trast to the other antiretroviral drugs, except IDV which
only caused crypt hyperplasia in the duodenum. Figure
2C illustrates the effects of both protease inhibitors and
reverse transcriptase on the intestinal villous length and
crypt depth.
B o t hN F Va n dI D Vi n c r e a s e dt h en u m b e ro fT U N E L
positive cells (apoptosis and possibly necrosis) signifi-
cantly by 89.6% and 180% compared to controls (cell
death is indicated by the brown staining of the cells
detected by the TUNEL method; Figure 3). AZT and
DDI did not cause a significant increase in the number
of TUNEL positive cells.
Intestinal Electrolyte and Water Absorption
NFV treatment caused significant increases in sodium
(167%), chloride (118.7%), and water (260%) secretion
when compared to controls. Likewise, IDV caused sig-
nificant increases, in sodium (97.5%), chloride (36.5%)
and water (95.7%) secretion. Treatment with AZT also
increased sodium (102.9%), chloride (36.6%) and water
(117.4%) secretion. Treatment with DDI increased only
sodium secretion (47.67%). (Figure 4)
Intestinal Absorption and Permeability
NFV treatment increased lactulose and mannitol excre-
tion significantly (p < 0.05). Lactulose excretion
increased from 1.32 ± 0.24% to 3.94 ± 0.68%. However,
mannitol excretion was also significantly increased from
3.014 ± 0.6% to 6.41 ± 1,08% after NFV chronic admin-
istration; hence there was no difference in the L/M
Effect of Antiretrovirals on Body Weight
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Figure 1 Effect of NFV (100 mg/kg), IDV (100 mg/kg), AZT (50
mg/kg) and DDI (100 mg/kg) on body weight in mice. Each
animal was weighed daily throughout the experiment. The results
are expressed as mean ± SEM of at least six mice per group.
*statistical significance (P < 0.05) compared to the PBS control
group by ANOVA, Bonferroni’s multiple test.
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IDV, AZT nor DDI treatment altered the excretion of
mannitol, lactulose or the L/M ratio (Figure 5).
2) In vitro experiments
Cell proliferation
The protease inhibitors, NFV and IDV, caused a signifi-
cant reduction in IEC-6 cell proliferation at both 24 h
and 48 h. NFV significantly inhibited cell proliferation at
doses of 7, 10, 70 and 100 ug/mL at 24 h (reduction of
18.1%, 26.1%, 48.1% and 39.1%, respectively; p < 0.05;
Figure 6A) and at 48 h (reduction of 29.5%, 49%, 46%,
48.2%, respectively; p < 0.05; Figure 6A). IDV at doses
of 50 ug/mL and 100 ug/mL significantly inhibited cell
proliferation by 8.6% and 17%, respectively, at 48 h and
by 15% at the dose of 100 ug/mL (p < 0.05; Figure 6B).
Slight (4.7%) but not significant inhibition of cell prolif-
eration was seen with AZT at the dose of 100 ug/mL at
48 h, with inhibition of 4.7%, which was not statistically
significant (Figure 6C; P > 0.05). Similarly, DDI
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Figure 2 Villus height (A) and crypt depth (B) after 7 days of treatment with either nelfinavir (NFV, 100 mg/kg), indinavir (IDV, 100
mg/kg), zidovudine (AZT, 50 mg/kg) and didanosine (DDI, 100 mg/kg) or PBS. For each animal, a total of 10 villi and 10 crypts were
measured for each segment of duodenum, jejunum, and ileum with a micrometer. The results are expressed as mean ± SEM of six mice per
group. *statistical significance (P < 0.05) compared to the PBS control group by ANOVA, Bonferroni’s multiple test. (C) Illustrative pictures of the
effects of CONTROL (PBS), NFV (100 mg/kg), DDI (100 mg/kg), IDV (100 mg/kg), AZT (50 mg/kg) on the intestinal jejunal tissue, showing
decreased villi length caused by all antiretrovirals and increased crypt depth caused by AZT.
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Page 6 of 13Figure 3 Illustrative pictures of the effects of antiretrovirals on cell death detected by TUNEL method (A) Negative-control (B) PBS
control, (C) DDI 100 mg/kg, (D) AZT 50 mg/kg, (E) IDV 100 mg/kg and (F) NFV 100 mg/kg on cell death, indicated by the brown
staining of the cells detected by the TUNEL method in the jejunal tissue, (G) Effects of the antiretrovirals on cell death, expressed as
average of number of TUNEL-positive cells. P < 0.05 when compared to control group (B) by one-way ANOVA and Bonferroni’s test.
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Page 7 of 13exposure did not show any significant inhibition of cell
proliferation at either 24 h or 48 h (Figure 6D).
Apoptosis and Necrosis
Triplicate flow cytometry analyses demonstrated a sig-
nificant increase in apoptosis in IEC-6 cells after 24 h
incubation with 70 ug/mL of NFV (Control: 4.7% vs
NFV: 22%; P = 0.0001; Figures 7 and 8). Slight, but
insignificant increases in IEC-6 cells apoptosis were seen
after 24 h of exposure to 100 ug/mL IDV, 100 ug/mL
AZT and 100 ug/mL DDI (Control: 4.7% vs IDV: 8.8%;
AZT: 9.9%; DDI: 7.4%; P: 0.29). There was a significant
increase in IEC-6 cell necrosis rates in IEC-6 after 100
ug/mL IDV or 70 ug/mL NFV(Control: 7.7% vs 16.0%;
P < 0.05 and 20.54%; P < 0.05), as shown in Figures 7
and 8. There were slight increases in necrosis with at
100 ug/mL AZT and 100 ug/mL DDI that were not sta-
tistically significant. Additionally, the apoptosis rates
were significantly higher with NFV than with IDV, AZT
or DDI apoptosis rates (P < 0.05 by one-way ANOVA
test).
Discussion
Gastrointestinal side effects of HAART are usually well
tolerated and do not contribute to significant treatment
discontinuation. However, diarrhea of moderate to
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Figure 4 Intestinal transport of fluid and electrolytes (mEq/
min/g) in experimental mice (n = at least 5 per group) after 7
days of treatment with either nelfinavir (NFV, 100 mg/kg),
indinavir (IDV, 100 mg/kg), zidovudine (AZT, 50 mg/kg) and
didanosine (DDI, 100 mg/kg) or PBS. Mice undergoing protease
and reverse transcriptase inhibitors were submitted to intestinal
perfusion (60 min) with ringer lactate. The results are expressed as
mean ± SEM of at least 5 mice per group. *statistical significance (P
< 0.05) compared to the PBS control group by ANOVA, Bonferroni’s
multiple test. A: sodium; B: chloride and C: fluid transport.
Figure 5 Lactulose and mannitol excretion (%) in experimental
mice (n = at least7 per group) following 7 days of treatment
with either nelfinavir (NFV, 100 mg/kg), indinavir (IDV, 100 mg/
kg), zidovudine (AZT, 50 mg/kg) and didanosine (DDI, 100 mg/
kg) or PBS. *statistical significance (P < 0:05) compared to the PBS
control group by ANOVA and Bonferroni’s multiple test.
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Page 8 of 13severe intensity can occur in patients receiving multi-
drug therapy [21-23]. The mechanisms underlying anti-
retroviral-induced diarrhea are unclear. The intestinal
epithelium acts as a highly selective barrier, preventing
the passage of toxic molecules and luminal bacterial
translocation [24]. The normal barrier function is main-
tained by steady enterocyte turnover finely regulated by
cell proliferation, migration, and apoptosis. Cell-to-cell
contacts within the intestinal epithelium structured by a
scaffold of tight and adherens junctions, located apically,
are further responsible for sealing the intestinal barrier
[25-27]. The results of this study suggest that selected
antiretroviral drugs influence small intestinal absorptive
and secretory functions.
We have assessed intestinal mucosal morphology, per-
meability changes, and electrolyte secretion following
antiretroviral treatment in mice. All antiretroviral agents
tested caused significant blunting of the absorptive villi,
especially in the duodenum and jejunum. Moreover,
hyperplasia of the crypt cells (which are responsible for
the secretory function of the small intestine) were some-
times, noted in the duodenum (IDV, AZT) and jejunum
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Figure 6 Effect of four different concentrations of nelfinavir (A), indinavir (B), zidovudine (C) and didanosine (D) on intestinal cell
proliferation after 24 h and 48 h of exposure by detected absorbance using an ELISA microplate reader at 420 nm in 96 well plates
seeded with IEC-6 cells. After an exposure time of 24 h and 48 h, with the antiretroviral drugs, 10 uL of the tetrazolium salt was added to each
well, and absorbance was measured after 4 h of incubation. * P < 0.05 when compared to control group (C) incubated in standard DMEM
media using one-way ANOVA and Bonferroni’s test.
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Page 9 of 13(IDV). While HIV, per se, and concomitant enteric
infections may cause mucosal atrophy [28,29], our find-
ings suggest that antiretroviral drugs may also contri-
bute to or aggravate any enteropathy secondary to
infectious causes. Mannitol and lactulose assays have
been very useful to assess overall intestinal absorptive
area (mannitol) and impaired epithelial barrier function
(lactulose), since both sugars are passively absorbed and
excreted unchanged into the urine [19,30]. Interestingly,
N F Vw a st h eo n l yd r u gt e s t e dt h a tc a u s e ds i g n i f i c a n t
increases in both lactulose and mannitol excretion rates,
thus not affecting the lactulose:mannitol ratio. We
A - Control                 B - NFV
C – IDV                                        D - AZT
             
E - DDI 
Figure 7 Rates of apoptosis and necrosis of control group (A), of 70 ug/mL of nelfinavir (B), 100 ug/mL of indinavir (C), zidovudine (D)
and didanosine (E) on intestinal epithelial IEC-6 cell apoptosis and necrosis after 24 h of exposure. Cells were stained with FITC-
conjugated annexin V and propidium iodide and analyzed by flow cytometry. Results are shown as density plots with propidium iodide vs.
annexin V-FITC. Viable cells have low annexin-V-FITC and low propidium iodide staining (lower-left quadrant), apoptotic cells have high annexin
V-FITC and low propidium iodide staining (lower-right quadrant), and necrotic cells have high propidium iodide and annexin V-FITC staining
(upper-right quadrant).
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Page 10 of 13speculate that NFV might have induced compensatory
changes in villus area following intestinal epithelial
injury. The other drugs tested did not show any signifi-
cant change in lactulose excretion suggesting that
epithelial tight junctions are not severely compromised
by these other antiretroviral drugs. Bode et al has also
described reductions in transepithelial electrical resis-
tance (TEER) in HT-29/B6 intestinal cell monolayers,
following exposure to NFV [7]. The effects of antiretro-
viral drugs on enterocyte tight junctions at the molecu-
lar level, however, remain to be explored. Interestingly,
only AZT induced crypt hyperplasia in both the duode-
num and jejunum compared with the other antiretro-
viral drugs (except IDV which only caused crypt
hyperplasia in the duodenum). Proximal intestinal area
reductions due to villus blunting and longer crypts can-
not be excluded. In contrast, net sodium, chloride and
water secretion are all significantly increased in animals
treated with all drugs, except DDI, indicating that effects
on electrolyte and water channels and thus, may help
explain the development of diarrhea. It has been pre-
viously reported that NFV recruits a slowly inactivating
basolateral Ca
2+ pathway, potentiating muscarinic Cl
-
secretion, which may lead to secretory diarrhea.
Interestingly, DDI did not c a u s ea ni n c r e a s ei nC l -o r
water transport, indicating a potentially different
mechanism of action.
In addition to the side effects of PI-induced-diarrhea,
HIV enteropathy and intestinal infections have also been
shown to cause intestinal villus blunting and atrophy,
leading to malabsorption [28,31]. We report in this
study significant decreases in cell proliferation and
increase in apoptotic and necrotic cell death in vitro,
caused by NFV. Cell proliferation and death are crucial
for the dynamic intestinal cell turnover process under
normal physiologic conditions, but these responses
become especially important during epithelial restitution
following injury from various causes. Recently, it has
been reported that NFV induces anchorage-independent
growth and a G1 cell cycle arrest in melanoma cells by
decreased activity of CDK2, a master kinase that regu-
lates G1-S progression [32]. We postulate that DDI does
not affect the cell cycle as does NFV, which would
explain the lack of effects on cell proliferation in vitro.
Previous studies have shown that PI’s cause significant
increase in apoptosis rates [7]. Recently, it has been
shown that PI’s activate the unfolded protein response
(UPR), the ER specific stress response, disrupting the
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Figure 8 Percentage of cell apoptosis, necrosis, and viable cells of the untreated control group, of 70 ug/mL of NFV, 100 ug/mL of
IDV, AZT and DDI on intestinal epithelial IEC-6 cell apoptosis and necrosis after 24 h of exposure. * P < 0.05 when compared to control
group (C) incubated in standard DMEM media and # P < 0.05 when compared to the nelfinavir group by one-way ANOVA and Bonferroni’s test.
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Page 11 of 13intestinal barrier integrity, and that reduction in CHOP
expression, which is a UPR-induced transcription factor
that mediates apoptosis, significantly reduced apoptosis
both in vitro and in vivo [33]. These findings further
help elucidate the different mechanisms by which HIV
PI’s can induce cell death in different cell lines. Indeed,
our study showed a similar increase in cell apoptosis in
groups treated with NFV both in vivo and in vitro.I n
addition, we also report a significant increase in necrosis
rates caused by IDV and NFV, which had not been pre-
viously reported [7].
Our in vitro and in vivo models do not take into
account other host and environmental variables includ-
ing HIV infection itself or opportunistic intestinal
pathogens that can certainly contribute to impaired
intestinal function and responses to antiretroviral agents.
HIV associated diarrhea may be partly related to mus-
carinic induced-chloride secretion [10]. Mucosal HIV
replication might induce a pro-inflammatory and Th1-
mediated cytokine over-expression [34], which could
additionally disrupt the intestinal barrier with increased
secretion with electrolyte and water loss. Depletion of
lymphocytes in the lamina propria by HIV could disrupt
the immune system and increase susceptibility to oppor-
tunistic infections [29,35]. Drug absorption may be
further compromised by opportunistic enteric infections
like Cryptosporidium spp. and Micromonospora spp.,
the former has been found in HIV-immunocompro-
mised patients in Brazilian settings, with and without
diarrhea [11,36,37]. Thus, a wide range of secretory
intestinal transport disruption may occur in vivo due to
direct antiretroviral therapy and both systemic and
intestinal infections.
Conclusion
In conclusion, this study focused on understanding the
effects of protease inhibitors and reverse transcription
antiretroviral drugs on the intestinal epithelium. Gaining
insight into how antiretroviral agents cause diarrhea is
essential in developing interventions that could poten-
tially reduce these side effects, avoid therapy disconti-
nuation and increase efficacy of the antiretroviral drugs.
We have found that both PI’s, NFV and IDV, decreased
proliferation and increased necrosis in vitro and that
only NFV increased apoptosis in vitro, in contrast to the
reverse transcriptase inhibitors which did not have such
an effect. Additionally, both PI’s and reverse transcrip-
tase inhibitors altered intestinal morphology in vivo,
reducing villous height in the duodenum and jejunum
and induced sodium secretion. Furthermore, NFV and
IDV induced cell apoptosis in vivo and chloride and
water secretion. NFV was the only drug tested that
caused significant changes in intestinal permeability.
Further studies are needed to elucidate molecular
mechanisms involved in HIV PI-induced epithelial
damage, including cell cycle studies, WNT-signaling and
R-spondin-1, specific cell death pathways as well as stu-
dies to examine whether cell migration and cellular
cytoskeletal F-actin are affected and contribute to dis-
rupting the intestinal barrier. Additionally, these
mechanisms might be modulated by important gut-
trophic nutrients, such as glutamine, alanyl-glutamine,
arginine and zinc [38], which could reduce intestinal
damage, increase drug absorption and decrease undesir-
able side effects, such as diarrhea that can be a limiting
factor for treatment adherence and efficacy.
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